After a meeting of its board of directors this morning, AstraZeneca Plc has issued a statement rejecting Pfizer Inc’s proposed cash and share takeover offer valued at £64 billion. The UK company described the financial and other terms as inadequate. ---Subscribe to MedNous to access this article--- Company News
